Anatara Lifesciences Ltd (ANR) AI Stock Analysis

Anatara Lifesciences Ltd

(ASX:ANR)

Select Model

Rating:44Neutral

Price Target:AUD 0.01▲(25.00% Upside)

Action:reiterated

Date:08/20/26

The score is driven primarily by weak financial performance—ongoing losses, zero revenue in 2026, and continued negative operating/free cash flow—partially offset by a cleaner balance sheet with zero debt and positive equity. Technical indicators also point to weak momentum (oversold RSI with slightly negative MACD), and valuation is constrained by a negative P/E and lack of dividend yield.

Positive Factors

Debt-Free Balance SheetZero debt reduces mandatory financing costs and near-term leverage risk, while positive equity provides a stronger capital base. This gives Anatara greater flexibility to fund development or pursue partnerships, although continued losses could reduce that cushion.

Negative Factors

Revenue DeteriorationThe loss of reported revenue leaves no established top-line base to support ongoing operations or validate commercial traction. Rebuilding consistent sales will be essential before Anatara can demonstrate recurring demand, operating leverage, or meaningful scale.

Anatara Lifesciences Ltd (ANR) vs. iShares MSCI Australia ETF (EWA)

Market Cap: AUD 2.53M
Dividend Yield: ―
Average Volume (3M): 500.98K
Price to Earnings (P/E): -2.4
Beta (1Y): 1.05
Revenue Growth: ―
EPS Growth: 64.58%
Country: Australia
Employees: 7
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Anatara Lifesciences Ltd Business Overview & Revenue Model

Company Description

Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointe...

How the Company Makes Money

null

Anatara Lifesciences Ltd Financial Statement Overview

Summary

Operating fundamentals are weak with persistent losses, negative operating profit, and negative net income, alongside volatile revenue that fell to zero in 2026 and negative gross profit. The balance sheet is comparatively stronger (zero debt in 2026 and positive equity), and cash burn improved in 2026, but operating and free cash flow remain consistently negative, keeping financing risk elevated.

Income Statement

12Very Negative

Balance Sheet

55Neutral

Cash Flow

22Negative

Financial statement breakdown
Breakdown	TTM	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022
Income Statement
Total Revenue	140.84K	0	969.46K	644.03K	0	0
Gross Profit	24.31K	-84	-633.97K	-748.91K	-24.76K	-24.68K
EBITDA	-1.25M	-1.25M	-1.96M	-1.46M	-3.21M	-2.97M
Net Income	-933.23K	-933.23K	-1.95M	-1.45M	-2.02M	-2.53M
Balance Sheet
Total Assets	820.39K	820.39K	1.15M	1.67M	1.42M	1.77M
Cash, Cash Equivalents and Short-Term Investments	470.92K	470.92K	101.36K	982.11K	401.18K	1.17M
Total Debt	0	0	407.42K	0	0	65.80K
Total Liabilities	108.86K	108.86K	612.42K	306.85K	494.83K	403.35K
Stockholders Equity	711.54K	711.54K	535.97K	1.36M	924.54K	1.36M
Cash Flow
Free Cash Flow	-339.24K	-339.24K	-2.27M	-1.25M	-2.26M	-2.24M
Operating Cash Flow	-339.24K	-339.24K	-2.27M	-1.25M	-2.26M	-2.23M
Investing Cash Flow	0	0	0	50.00K	-1,726	-56.56K
Financing Cash Flow	708.80K	708.80K	1.39M	1.83M	1.49M	-22.44K

Anatara Lifesciences Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

AU:ANR against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:BIO	79Outperform	AUD 83.31M	21.12	46.74%	―	29.68%	1520.00%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:RCE	46Neutral	AUD 110.10M	-6.66	84.67%	―	―	42.51%
AU:IMC	45Neutral	AUD 12.91M	-3.10	-31.88%	―	5.85%	45.13%
AU:EZZ	44Neutral	AUD 14.35M	-2.56	-20.36%	13.62%	-30.79%	-177.68%
AU:ANR	44Neutral	AUD 2.53M	-2.35	-101.34%	―	―	64.58%
AU:BOT	41Neutral	AUD 27.63M	-0.28	-118.74%	―	499.47%	31.20%

* Healthcare Sector Average

Performance Comparison

AU:ANR and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
AU:ANR	Anatara Lifesciences Ltd	0.01	0.00	0.00%
AU:IMC	Immuron Limited	0.04	-0.04	-48.72%
AU:BOT	Botanix Pharmaceuticals Limited	0.01	-0.12	-92.31%
AU:EZZ	EZZ Life Science Holdings Ltd.	0.29	-1.92	-86.66%
AU:BIO	Biome Australia Ltd	0.35	-0.12	-24.73%
AU:RCE	Recce Pharmaceuticals Ltd.	0.35	-0.05	-12.35%

Anatara Lifesciences Ltd Corporate Events

Anatara Lifesciences Narrows Annual Loss but Faces Going-Concern Warning

Aug 18, 2026

Anatara Lifesciences Ltd is a biotechnology company focused on developing therapeutic products, with its activities reflected through consolidated financial reporting for the group. The company operates without paying dividends, indicating an emphasi...

Anatara Advances Anti-Obesity Candidate AOC and GaRP IBS Program Amid Strategic Review

Jul 31, 2026

Anatara Lifesciences reported Q4 FY26 progress on its Anti-Obesity Project, where pre-clinical studies identified a candidate compound, AOC, showing statistically significant effects in attenuating post-semaglutide weight regain and reducing visceral...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 20, 2026

Anatara Lifesciences Ltd AI Stock Analysis